Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Icon ( (ICLR) ) is now available.
On April 27, 2026, ICON plc’s audit committee concluded that investors should no longer rely on the company’s audited 2023 and 2024 financial statements and unaudited quarterly results from March 31, 2023 through September 30, 2025, due to revenue recognition issues that overstated revenue. The company emphasized that these accounting issues did not affect customers, operations or cash flow, and that the revenue overstatements in 2023 and 2024 were below a previously indicated 2% upper limit, with a smaller impact identified in 2025.
ICON plans to restate its financials for 2023, 2024 and the first nine months of 2025, incorporating these corrections into its 2025 Form 20-F and amending prior interim filings, which will also disclose material weaknesses in internal controls and remediation plans. Management expects to finalize 2025 financial statements and complete the external audit in the coming weeks, a process that may lead to material changes to preliminary 2025 results and carries implications for regulatory compliance, investor confidence and the company’s internal control framework.
The most recent analyst rating on (ICLR) stock is a Hold with a $120.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
The score is driven primarily by solid financial strength (low leverage and strong revenue growth) but tempered by declining margins and weak TTM free cash flow growth. Technicals are supportive with price above major moving averages, while the earnings call was balanced—strong awards and cash generation offset by cancellations and pricing pressure. Valuation is reasonable but not distinctly cheap at a ~25.4 P/E.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc is a world-leading clinical research organization headquartered in Dublin, Ireland, providing integrated consulting, clinical development, commercialization and post-marketing solutions. The company serves pharmaceutical, biotechnology, medical device, government and public health clients worldwide, employing about 40,100 staff across 97 locations in 55 countries as of December 31, 2025.
Its global scale, specialized medical and operational expertise, and investments in advanced technology position ICON as a key outsourcing partner in drug and device development. The company’s strategy focuses on commercial execution, large pharma relationships and leveraging improved demand trends to drive sustained long-term growth in the clinical research market.
Average Trading Volume: 1,933,206
Technical Sentiment Signal: Sell
Current Market Cap: $7.88B
See more data about ICLR stock on TipRanks’ Stock Analysis page.